◆英語タイトル:Shield Therapeutics Plc (STX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8196
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Shield Therapeutics Plc (Shield Therapeutics) is a specialty pharmaceutical company that focus on the development and commercialization products for the treatment of anaemia associated with renal and gastrointestinal disorders. The company’s product portfolio includes Feraccru, a stable, non-salt, oral formulation of ferric iron-based pharmaceutical product used to treat iron deficiency anaemia (IDA). Shield Therapeutics provides PT20, an iron-based phosphate binder, developed to treat hyperphosphatemia related to dialysis-dependent or dialysis-independent chronic kidney disease (CKD). The company operates has operations in the UK, Germany and Switzerland. Shield Therapeutics is headquartered in Gateshead, the UK.
Shield Therapeutics Plc (STX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Shield Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Phosphate Therapeutics Raises US$13.85 Million In Venture Financing 10
Licensing Agreements 11
Norgine Enters into Licensing Agreement with Shield Therapeutics 11
Ewopharma Enters into Licensing Agreement with Shield Therapeutics 12
Phosphate Therapeutics Enters Into Licensing Agreement With Medical Research Council For PT20 13
Equity Offering 14
Shield Therapeutics to Raise USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 14
Shield Therapeutics Raises USD13 Million in Private Placement of Shares upon Excercise of Warrants 15
Shield Therapeutics Raises USD2 Million in Private Placement of Shares 16
Shield Therapeutics Raises USD47 Million in IPO 17
Acquisition 19
Shield Therapeutics Acquires Phosphate Therapeutics for USD37.6 Million 19
Shield Therapeutics Plc – Key Competitors 20
Shield Therapeutics Plc – Key Employees 21
Shield Therapeutics Plc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Sep 19, 2018: Shield Therapeutics announces interim report for the six months ended 30 June 2018 23
Jul 23, 2018: Shield Therapeutics: H1 Business Update 26
Apr 11, 2018: Shield Therapeutics: Preliminary Results for the Year Ended 31 December 2017 28
Sep 20, 2017: Shield Therapeutics: Interim Report for the Six Months Ended 30 June 2017 31
Apr 04, 2017: Shield Therapeutics Announces Preliminary Results for the Year Ended 31 December 2016 33
Corporate Communications 34
Jun 05, 2018: Shield Therapeutics Announces Directorate Change 34
Apr 06, 2018: Shield Therapeutics: Appointment of Non-Executive Director 35
Sep 14, 2017: Shield Therapeutics: Board Change 36
Apr 04, 2017: Shield Therapeutics Announces Appointment of Chief Financial Officer 37
Product News 38
01/06/2017: Shield Therapeutics Provides Update on PT20 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List of Tables
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Shield Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Shield Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Phosphate Therapeutics Raises US$13.85 Million In Venture Financing 10
Norgine Enters into Licensing Agreement with Shield Therapeutics 11
Ewopharma Enters into Licensing Agreement with Shield Therapeutics 12
Phosphate Therapeutics Enters Into Licensing Agreement With Medical Research Council For PT20 13
Shield Therapeutics to Raise USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 14
Shield Therapeutics Raises USD13 Million in Private Placement of Shares upon Excercise of Warrants 15
Shield Therapeutics Raises USD2 Million in Private Placement of Shares 16
Shield Therapeutics Raises USD47 Million in IPO 17
Shield Therapeutics Acquires Phosphate Therapeutics for USD37.6 Million 19
Shield Therapeutics Plc, Key Competitors 20
Shield Therapeutics Plc, Key Employees 21
Shield Therapeutics Plc, Other Locations 22
Shield Therapeutics Plc, Subsidiaries 22
List of Figures
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Shield Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8